Composition
Tab 50 mg/150 mg: Bicalutamide 50 mg/150 mg.
Indications & Dosage
Locally advanced prostate cancer at high risk of disease progression either alone or as adjuvant treatment to prostatectomy or radiotherapy, Locally advanced, non-metastatic prostate cancer when surgical castration or other medical intervention inappropriate: Adult: 150 mg once daily. Advanced prostate cancer, in combination with gonadorelin analogue or surgical castration: Adult: 50 mg once daily, to be started at the same time as surgical castration or at least 3 days before gonadorelin therapy.
Precautions
Risk of photosensitivity; avoid excessive exposure to UV light and sunlight during treatment. Moderate, to severe hepatic impairment. Consider periodic liver function tests; discontinue if changes are severe. Consider withdrawing in patients with objective progression of disease together with elevated PSA.
Interactions
Cisapride, astemizole, cimetidine, ketoconazole, oral anticoagulants, cyclosporin, calcium antagonists, drugs metabolised by CYP3A4.
Side Effects
Alopecia , anaemia, asthenia, breast tenderness, cholestasis, depression, dizziness, dyspepsia, gynaecomastia , haematuria, hepatotoxicity, hirsutism, impotence, jaundice, nausea, oedema, pruritus, somnolence, angioedema, hypersensitivity reactions, interstitial lung disease, urticaria. Rare Hepatic failure, photosensitivity reactions